36 results about "Subcutaneous injection" patented technology

Most therapeutic treatments require dose adjustment after initial administration. Dosage adjustment is crucial to ensuring optimal safety and efficacy characteristics of the treatment. Gene therapy is inherently limited by the inability to adjust the dose after initial administration. This invention describes a genetic element capable of dose adjustment after the initial administration of gene therapy. The realization of dose adjustment allows for the replacement of multiple subcutaneous protein injection regimens with single-injection gene therapy, thereby improving pharmacokinetics, safety / efficacy characteristics, medication adherence, and reducing healthcare costs.

A pharmaceutical combination for subcutaneous administration and use thereof are provided. The pharmaceutical combination as described herein for subcutaneous administration includes a hyaluronidase and an antibody-drug conjugate. The antibody-drug conjugate includes a fragment of a bioactive molecule, and the bioactive molecule has moderate toxicity. The pharmaceutical combination can achieve a larger volume and a larger dose of administration, and the side reaction is not enhanced.

The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 600 mg to about 1000 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

This invention belongs to the field of vertebrate technology, specifically relating to a method for constructing a complex inflammatory animal model in middle-aged and elderly individuals and its related applications. The method includes: selecting adult animals for adaptive feeding, daily subcutaneous injection of D-galactose to establish a susceptibility to aging and oxidative stress, and administering sodium dextran sulfate (DSS) solution within a specific time window to induce intestinal inflammation, forming a complex inflammatory state through gut-hepatic axis interactions. The constructed animal model simultaneously exhibits intestinal inflammatory damage, abnormal hepatic oxidative stress, and aging-related characteristics, realistically simulating the pathological process of gut-hepatic axis dysfunction in middle-aged and elderly individuals. This model is suitable for screening and evaluating drugs, medical nutrition products, and functional foods that improve gut-hepatic axis dysfunction, providing a reliable technical platform for research on related disease mechanisms and the development of interventional substances.

The present invention relates to nanoparticles comprising sirolimus and albumin, a pharmaceutical composition comprising the same for subcutaneous administration, and a method for preparing the same. In the case of using the preparation method of the present invention, nanoparticles comprising sirolimus and albumin having excellent stability of particle size distribution can be prepared, the prepared nanoparticles can be prepared as a pharmaceutical composition suitable for subcutaneous injection, and the increase in administration dose and the convenience of administration can be improved.

This utility model discloses a portable syringe plunger auxiliary device, comprising: a base and a power supply module. A syringe holder and an electric plunger are mounted on the base; the syringe holder is configured to engage an injection syringe; the electric plunger is positioned such that its output shaft extends toward the syringe holder, and the electric plunger pushes the piston handle of the injection syringe engaged in the syringe holder toward the needle tip of the injection syringe; the power supply module is installed within the base and electrically connected to the electric plunger through a first power supply circuit, and the power supply module supplies power to the electric plunger. This utility model helps nursing personnel achieve a stable and uniform injection operation over a long period during subcutaneous injections.

1. The name of the design product: insulin injection simulation artificial skin. 2. The use of the design product: the product is mainly used to demonstrate injection site selection and injection process in subcutaneous injection education process. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best indicates the design points: perspective view. 5. The design for which protection is sought contains color. 6. The back of the design product is a part that is not easy to see or cannot be seen during use, and the rear view is omitted.

The present invention relates to a composition comprising a photosensitizer use in prevention or treatment of dermatological disease in a patient, wherein the composition is used in the following order of steps: (a) topical application or subcutaneous injection of said composition to an area of the skin of said patient, (b) exposure of at least said area of the skin to light with a wavelength spectrum similar or identical to sun light for a duration of 30 min to 5 hours, and (c) exposure of at least said area of the skin to light of a wavelength spectrum comprising only one maximum in the absorbance spectrum of said photosensitizer as well as to methods of treating dermatological disease using the outlined steps and kits of parts comprising such compositions and light sources suitable to apply the respectively indicated light.

The present application relates to a method of treating migraine or cluster headache in a human patient, said method comprising administering subcutaneously composition comprising sumatriptan or its pharmaceutically acceptable salt, in an amount equivalent to 3 mg sumatriptan base.

The present disclosure provides a storage-stable solid composition comprising a biopharmaceutical agent and a polyacrylamide-based copolymer. The present inventors have demonstrated that particular polyacrylamide-based copolymers can be used as stabilizing excipients in lyophilized formulations of biopharmaceutical agents. Methods of reconstituting and using the compositions are also provided, including methods of administering the reconstituted compositions to a human subject in need thereof by injection, e.g., subcutaneous injection.

Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.

The objective invention provides a parenteral composition of semaglutide or a pharmaceutically acceptable salt thereof for subcutaneous administration, having a strength and composition such that it can be administered multiple times from single article of manufacture, for use in treating type 2 diabetes mellitus and for weight loss, thereby providing benefit to the patient.

The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 1000 mg to about 1800 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 500 mg to about 900 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.

The present invention relates to a pharmaceutical preparation for subcutaneous administration, the preparation comprising: an antibody-drug conjugate (ADC); and native human recombinant hyaluronidase PH20.

The present invention relates to a method of TNF-α related disease by subcutaneously administering an antibody binding to TNF-α (anti-TNF-α antibody). A treatment method, composition, kit or use according to the present invention reduces the time for administration and the time for patients to stay in hospitals, thereby improving patient convenience and the quality of life of the patient. This provides the advantage of improving the patient's satisfaction.

The present invention discloses an antibiotic pharmaceutical composition for intradermal or subcutaneous administration, comprising an antibiotic and hyaluronidase. The present invention also relates to a kit comprising said pharmaceutical composition, a method for preparing said kit, and uses of said pharmaceutical composition and kit.

The present invention relates to microparticles comprising tirzepatide or a pharmaceutically acceptable salt thereof and a manufacturing method therefor, wherein the content of tirzepatide or a pharmaceutically acceptable salt thereof is increased in the microparticles, thereby increasing the loading amount of a drug in the microparticles and exhibiting an effect of continuously releasing tirzepatide or a pharmaceutically acceptable salt thereof from the microparticles without initial over-release and lag time, thus preventing an excessive decrease in bioavailability. In addition, when the microparticles are used as a subcutaneous injection, the amount of microparticles included for one injection can be reduced, thereby reducing pain at the site of administration and causing no inflammatory response.

Anti-alpha4beta7 integrin antibody liquid formulations are described that have a high concentration of antibody, e.g., 90 mg / ml or more, have a viscosity suitable for injection for subcutaneous delivery, including by self-administration by the patient. In certain embodiments, formulations can be used in combination with an autoinjector having a suitable force of delivery given the viscosity of the formulation.

The present invention provides compositions and related methods for treating interleukin-5 (IL-5) mediated diseases in children. [Solution] A method for treating a disease in a child, comprising the steps of: a) identifying a child weighing less than 40 kg who has a disease selected from the group consisting of asthma, mild asthma, moderate asthma, severe asthma, mild eosinophilic asthma, moderate eosinophilic asthma, severe eosinophilic asthma, poorly controlled eosinophilic asthma, etc.; and b) subcutaneously administering a therapeutically effective dose of mepolizumab to the child, wherein the therapeutically effective dose of the antibody results in a maximum plasma concentration (Cmax) of antibody of approximately 10.1960 ± 0.3345 μg / mL and an area under the curve [0-infinity] value of approximately 454.39 ± 15.8876 μg* / mL, thereby treating the disease in the child.

The present disclosure provides, among other things, methods and compositions for the oral administration of polypeptides. Many polypeptides are typically administered in liquid solutions by intravenous or subcutaneous injection. The present disclosure provides methods and compositions that include a polypeptide formulation for oral delivery that includes a core and a pharmaceutically acceptable capsule, where the core includes an amorphous polypeptide composition or a crystallized polypeptide composition and a pharmaceutically acceptable carrier comprising a vitamin E agent.

The present invention relates to a method for treating TNFα-related diseases by subcutaneously administering an antibody (anti-TNFα antibody) that binds to TNFα or an antigen-binding fragment thereof. A treatment method, a composition, a kit, or a use according to the present invention provides the advantage that administration time is reduced compared to intravenous injections and the amount of time that patients stay in hospitals is reduced, and thus patient satisfaction is increased through improved convenience and improved quality of life. In particular, the present invention has the advantage of providing a therapeutic agent that is highly effective in improving medication convenience, disease treatment effects, growth disorders, and the like with respect to pediatric / adolescent patients suffering from autoimmune diseases.

The application relates to the technical field of medical instrument equipment, in particular to an auxiliary positioning projection device for low-molecular heparin abdominal injection, which comprises a base, a suction cup fixedly connected to the bottom of the base, the suction cup being adsorbed directly above the navel, and a projection positioning mechanism arranged at the top of the base. The hollow lead screw, the internal thread ring, the projection lamp, the limiting column, the limiting ring, the knob and the press-type power module are arranged, the hollow lead screw and the internal thread ring are in a threaded sleeve joint cooperation relationship, the projection lamp can move on the hollow lead screw through the internal thread ring, the projection position is adjusted, the device can position and project the subcutaneous injection area of a patient through the projection lamp, and the effect that the patient can accurately find the injection point is achieved. The small air pump, the partition plate and the air pump mounting disc are cooperated, the device can firmly adsorb the suction cup above the navel through negative pressure, and the effect that the silica gel ball can accurately position the projection aperture is achieved.

This invention provides a subcutaneous insulin pen, an intelligent annotation system, and a method. It improves upon traditional insulin pens by installing a subcutaneous detection module at the pen tip. This module uses non-contact detection technologies, such as ultrasound, to detect abnormalities in subcutaneous tissue and nodules. The module then uploads the analysis results to a backend server via a signal analysis module. Nurses, patients, and family members can directly view skin data via a mobile app connected to the insulin pen before injection to assess whether the skin at that location is suitable for injection. This enables precise in-situ detection, automated assessment, safety management, intelligent interpretation, and full-cycle health management before insulin injection, fundamentally addressing the safety concerns of home insulin injection and overcoming all the shortcomings of existing technologies.

This invention belongs to the field of pharmaceutical formulation technology, specifically relating to a bortezomib lyotropic liquid crystal precursor composition, its preparation method, and its application. The bortezomib lyotropic liquid crystal precursor composition comprises bortezomib and a lyotropic liquid crystal carrier, wherein the ratio of bortezomib to the lyotropic liquid crystal carrier is 0.8-10 mg:1 mL; the lyotropic liquid crystal carrier comprises soybean phosphatidylcholine, α-tocopherol, dioleoylglycerol, and anhydrous ethanol in a mass ratio of 40-48:30-40:10:10-15. Experimental verification shows that the bortezomib lyotropic liquid crystal precursor composition provided by this invention can be converted into a structurally stable liquid crystal phase after subcutaneous injection, achieving effective encapsulation and slow release of bortezomib, thereby significantly prolonging the drug's duration of action in vivo, reducing local reactions, and exhibiting long-acting, safe, and stable characteristics.

Provided are combination therapies comprising inavolisib and a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for the treatment of HER2-positive cancers; and methods of treating a PIK3CA mutated, HER2 positive (HER2+) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib and PH FDC SC.

This invention provides a method and unit dose for the treatment of type I IFN-mediated diseases. [Solution] The present invention provides a unit dose for subcutaneous administration of a type I IFN receptor (IFNAR1) inhibitor in a dose greater than 105 mg (>) and less than 150 mg (<), specifically a human monoclonal antibody specific to IFNAR1, or optionally a modified IgG1 class human monoclonal antibody, and a method comprising subcutaneously administering the unit dose to a subject having a type I interferon (IFN)-mediated disease.